Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on APLS stock, giving a Buy rating yesterday. Tazeen Ahmad ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $36.73 which represents a slight increase of $1.10 or 3.09% from the prior close of $35.63. The stock opened at $36.24 ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.47, ...

Apellis Pharmaceuticals Inc (APLS) stock saw a decline, ending the day at $38.36 which represents a decrease of $-0.82 or -2.09% from the prior close of $39.18. The stock opened at $38.97 and touched ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 4.4% on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $64.00 to $57.00. JPMorgan Chase ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...